Table 3.
Association between AD neuropathological burden and functional cognitive scores with one or two non-European APOE alleles (local APOE ancestry) in APOE4- individuals (n = 235, see Fig. 1 for grouping criteria).
| Model 1 (without AFR adjustment) | Model 2 (with AFR adjustment) | ||||
|---|---|---|---|---|---|
| Outcomes | Pathology adjustments | β (95% CI) | p | β (95% CI) | p |
| BB | NA | −0.12 (−0.46; 0.22) | 0.493 | −0.23 (−0.63; 0.17) | 0.263 |
| CERAD | NA | −0.27 (−0.48; −0.05) | 0.015 | −0.28 (−0.53; −0.02) | 0.032 |
| CDR-SOB | NA | 0.35 (−0.72; 1.42) | 0.518 | 0.35 (−0.92; 1.62) | 0.585 |
| BB + CERAD | 0.89 (−0.07; 1.86) | 0.069 | 1.00 (−0.14; 2.15) | 0.084 | |
| BB | 0.46 (−0.52; 1.43) | 0.358 | 0.53 (−0.63; 1.69) | 0.372 | |
| CERAD | 1.01 (0.04; 1.99) | 0.041 | 1.11 (−0.04; 2.26) | 0.059 | |
Reference: Individuals EUR APOE4- alleles (genotypes 22, 23 or 33) (n = 138).
Model 1: Linear regression model adjusted for age, sex, education, and AD neuropathology when indicated.
Model 2: Linear regression model adjusted for age, sex, education, AD neuropathology when indicated, and AFR.
AFR African ancestry (continuous 10% increments), BB Braak & Braak, CERAD Consortium to Establish a Registry for Alzheimer’s disease, CDR-SOB clinical Dementia Rating sum of boxes, NA not applicable.